

# Embedding sustainability capabilities in medicines manufacturing operations

1 July 2025  
11:00 – 12:00  
Webinar

[www.iuk.ktn-uk.org](http://www.iuk.ktn-uk.org)



Innovate  
UK

Business  
Connect



Introducing

# Biopharmaceutical Environmental Excellence Maturity Model

Webinar



CONNECT  
COLLABORATE  
ACCELERATE™



# Speakers



**Nicola Coles**

Phorum Director,  
Sustainability



**Clare Thompson**

Global Change  
Facilitator



**Darryl Ratty**

Executive Director,  
Global ESG



**Shahida Hamid**

Director,  
Global Sustainability



**Karl Britt**

Vice President,  
Sustainability and Innovation



# Agenda

- Introduction to BioPhorum and why we are all together
- What was the gap that the BEEMM is filling
- What has been developed to fill the gap
- Use cases:
  - Internal road mapping (single site or multi-site)
  - Industry picture and benchmarking
  - Conversations with LH/CM/suppliers
- Current programme
- Ask: Do you want to get involved, use the model, or be involved with BioPhorum to support building the data set?



To accelerate industry-wide transformation we focus on five key areas.

**Improved productivity and cost reduction**  
to bring more treatments to market profitably

**Increased speed to market**  
to save hundreds of millions of dollars on treatments

**Regulatory risk and simplification**  
identifying opportunities for streamlining

**Sustainability**  
improving environmental performance by tackling key issues around energy, emissions and materials

**Workforce enablement**  
supporting the recruitment, training and nurturing of skilled talent

**The biopharmaceutical industry's most trusted collaborative environment for change**

BioPhorum delivers truly collaborative outcomes which allow us to accelerate change by approaching industry agencies as **one authoritative voice.**

To find out more, visit **[biophorum.com](https://biophorum.com)**

# BioPhorum: a co-ordinated program of industry change

BioPhorum's mission is to create an environment where our members from the global biopharmaceutical and device industries connect, collaborate and accelerate progress – for the benefit of all.



**Member-led**



**Safe and confidential**




**Cheaper, faster and better journeys**



**Consensus-driven**

This allows for cost reduction, lower waste, improved productivity, better environmental performance across the value chain, better investment decisions and the cost of poor decisions avoided.

There are currently 11 Phorums providing a wealth of opportunities for companies to align their interests with similarly committed organizations.



**150+**  
member companies

**200+**  
global programs for change

**7500**  
leaders and subject matter experts

**170+**  
published papers, presentations and resources in the last 12 months

# Environmental Sustainability Vision

Improving patient health by providing biopharmaceuticals while respecting the planet and responsibly using its resources



## QUIZ

**What is biopharmaceuticals' impact on the environment**

(True or False)





The healthcare industry's carbon footprint is higher than the commercial aviation industry.



True

Health care's climate footprint is equivalent to 4.4% of global net emissions (2 gigatons of carbon dioxide equivalent). If global healthcare was a country, it would be the 5th highest emitter.



The biopharmaceutical industry is estimated to produce around 300 million tonnes of plastic waste every year.



True

The biopharmaceutical industry generates around 300 million tons of plastic waste annually. Much of this plastic is single-use, which poses significant challenges for waste disposal and handling.



Global Environmental, Social and Governance (ESG) regulations have increased by 155% over the past decade.



True

This surge is driven by the rapid growth of sustainability-based policy interventions, which are shaping financial markets and increasing the complexity of the global reporting landscape.



Out of 150 BioPhorum members, 54 have signed up to the Science Based Targets Initiative (SBTi).



False

86 members (which includes license holders, CDMOs and suppliers) have signed up to SBTi. As of 2024, nearly 10,000 companies have science-based climate targets validated by SBTi.



# The Biopharmaceutical Environmental Excellence Maturity Model (BEEMM)

To achieve our vision, the BioPhorum Sustainability community have developed an Environmental Sustainability Maturity Model specifically for the biomanufacturing, providing a strategic framework to progressively minimize environmental impact.

The maturity model aims to help the industry achieve the following goals:


- **Reduce GHG emissions**
- **Reduce waste**
- **Reduce water**
- **Reduce impact on nature and biodiversity**

To do this maturity model allows biomanufacturers and suppliers identify their gaps in tools, technology and processes to:

- **Reduce emissions across their scope 1, 2 and 3**
- **Embed circular design and principles**
- **Establish data transparency across the whole value chain**
- **Sourcing sustainable raw materials**




# Structure of the model and example tracks



# Activating sustainability at the heart of manufacturing


A **cross-value** chain community of license holders, CDMOs and suppliers

**Driving environmental excellence of the biomanufacturing process** from cradle to grave



# Use cases: End-to-end value chain and cross-organisation conversations


## Bio-based plastics example



Source 1 - Cytiva

### Product and process development: Manufacturing Approach and Single-Use Technology Selection

SUPPO	Single-Use Technology (SUT) Design	Is at least one SUT product made from recyclable material?	Is at least one SUT product designed to enable easy disassembly and increased recyclability of components (e.g. reducing surface contact of components to biohazard waste to allow for disassembly and recycling)?	Is there a programme in place to improve the disassembly and recyclability of all SUT products?	Do you have at least one non-fossil derived (bio-based plastic) SUT product available to customers (product successfully passed extractable and leachate testing)?	Is there one SUT product designed for remanufacture to support take-back scheme pilots with customers?
		Is there a programme in place to expand the use of recyclable, non-virgin or non-fossil derived material across all SUT products?	Is there a pilot in place to create a version of a SUT which has multiple uses, or components with multiple uses (e.g. LCA data to support lower environmental impact considering cleaning procedures)?	Do you have multiple non-virgin or non-fossil derived (bio-based) SUT products available to customers?	Do you have multiple non-virgin or non-fossil derived material (where proven through LCA to have lower environmental impact)?	Is there at least one SUT product designed for remanufacture to support customer take-back schemes available to customers?




Source 2 - Cytiva

### Product and process development: Single-Use Technology (SUT) Design

SUPPO	Manufacturing Approach and Single-Use Technology Selection	When designing the manufacturing approach and selecting technology is environmental impact assessed to mitigate impact of the manufacturing process?	When selecting stainless steel, do you consider water use and chemical waste during on-cleaning processes?	When selecting SUT, do you consider waste management processes and recyclability of components, where compatible plastic can be recycled together?	When selecting SUT, do you prioritise waste management processes with lower environmental impact (e.g. disassembly and recyclability of components)?	Have you collaborated with a supplier to pilot a multiple-use version of a commonly used SUT product, or SUT product with one multiple-use component?	Do you commonly select multiple-use versions of SUT products or SUT products with multiple-use components?	Are the majority of SUT selected disconnected from heat lab feedbacks?	Do you utilize multiple SUTs with take-back schemes for SUT products with your suppliers?
		When designing the manufacturing approach and selecting technology is environmental impact assessed to mitigate impact of the manufacturing process?	When selecting SUT, do you consider waste management processes and recyclability of components, where compatible plastic can be recycled together?	When selecting SUT, do you prioritise waste management processes with lower environmental impact (e.g. disassembly and recyclability of components)?	Have you selected at least one SUT which is made from non-fossil derived materials (e.g. bio-based plastic)?	Have you collaborated with a supplier to pilot at least one SUT product which has take-back scheme for remanufacture?	Are the majority of SUT selected disconnected from heat lab feedbacks?	Do you utilize multiple SUTs with take-back schemes for SUT products with your suppliers?	

Source 1 – Cytiva: [https://www.cytivalifesciences.com/en/us/knowledge-center/Process-considerations-for-closed-connected-processing?srsltid=AfmBOormO\\_D0oALpJ6zBdLlpSxYGMVq\\_gYMvHfbEsT3Z7kh2xY2qKdwR](https://www.cytivalifesciences.com/en/us/knowledge-center/Process-considerations-for-closed-connected-processing?srsltid=AfmBOormO_D0oALpJ6zBdLlpSxYGMVq_gYMvHfbEsT3Z7kh2xY2qKdwR)  
Source 2 – Cytiva: <https://www.cytivalifesciences.com/en/us/shop/cell-culture-and-fermentation/rocking-bioreactors/consumables-and-accessories/single-use-readytoprocess-wave-cellbag-bioreactors-p-00346/parts-and-accessories/28412268/accessories>

# Use cases – Industry picture



Note: Test data for illustration only

# Use cases – Industry picture

Overall Strategy & Data	Global Sustainability Strategy	Environmental Goals and Public Disclosure	Roadmaps	Metrics and Progress Reporting	Horizon Scanning	Collaborations	Regulation	People, Culture and Training	Data Storage
LH	4.2	3.8	3.9	3.8	3.4	4.5	4.1	2.1	0.3
CDMO	3.9	3.5	3.2	3.5	3.0	4.1	4.2	2.0	0.2
SU	3.8	3.1	3.3	3.6	3.5	4.3	3.7	2.5	0.8

Overall Product & Process Development	Eco-design culture	Environmental Impact Data and Tools	Chemicals	Manufacturing Approach and Single-Use Technology Selection	Process Intensification	Drug Delivery Device Design (specifically auto-injectors and pens)	Excess Product (Use of sold products (scope 3 category 11))	Single Use Technology Design
LH	1.7	1.3	2.2	1.4	2.2	0.9	1.7	
CDMO	0.8	0.3	1.9	1.0				
SU	2.0	2.4	1.4					1.1

Overall Procurement	Procurement strategy	Supplier Engagement (scope 3 category 1)	Localised supply	Packaging	Overall Use and End of Life	End-of-life Treatment of Sold Products (scope 3 category 12)
LH	2.0	2.1	2.8	0.8	LH	1.8
CDMO	1.3	1.9	1.5	0.3	CDMO	
SU	2.2	2.3	2.0	1.0	SU	0.3


Overall Out-Bound Supply	Downstream transportation and distribution decarbonization strategy (scope 3 category 9)	Downstream Supply Chain Network Optimization	Lower Carbon Transportation Options	Renewable Fuel Options	Cold Chain	Shipment Loads	Transportation and Distribution Packaging	Reverse Logistics	Overall In-Bound Supply	Upstream Transportation and Distribution Decarbonization	Upstream Supply Chain Network Optimization	Inventory Management	Reverse Logistics
LH	1.3	0.8	1.3	1.3	2.0	2.0	0.5	0.7	LH	1.0	0.8	1.0	2.0
CDMO	2.0	0.5	1.0	0.0	0.0	1.0	1.0	0.0	CDMO	1.3	0.8	1.0	1.0
SU	2.3	0.5	2.3	0.5	0.8	2.3	1.1	0.4	SU	2.0	0.9	2.8	2.5

Overall Facilities and Manufacturing	Facility Environmental Performance Strategy	Energy Source at Facilities (scope 1 and 2)	Heat generation	Facility design (scope 3 category 2)	Machinery and manufacturing processes (scope 3 category 2)	Heating, Ventilation, and Air Conditioning (HVAC) Optimization (scope 1 and 2)	Biomanufacturing chemicals	Waste Management (scope 3 category 5)	Single-Use Technology (SUT) Waste Management	Water Stewardship	Water Monitoring and Data	Water Reduction	Water Recycling
LH	1.8	2.9	2.6	0.0	1.4	1.2	0.4	1.9	0.8	2.6	1.6	1.5	1.2
CDMO	2.9	2.3	1.3	0.0	2.0	1.3	1.0	1.5	1.5	2.0	1.0	1.1	1.0
SU	2.8	2.1	2.8	0.0	1.5	1.0	1.0	1.8		0.8	1.3	1.8	0.5

Note: Test data for illustration only





# Use cases – Benchmarking and internal roadmaps



Note: Test data for illustration only





Internal opportunities to address in organisation roadmaps

# Use cases – Collaboration across the value chain



Overall Strategy & Data	Global Sustainability Strategy	Environmental Goals and Public Disclosure	Roadmaps	Metrics and Progress Reporting	Horizon Scanning	Collaborations	Regulation	People, Culture and Training	Data Storage
LH	4.2	3.8	3.9	3.8	3.4	4.5	4.1	2.1	0.3
CDMO	3.9	3.5	3.2	3.5	3.0	4.1	4.2	2.0	0.2
SU	3.8	3.1	3.3	3.6	3.5	4.3	3.7	2.5	0.8

# BioPhorum Sustainability: Achievements to date

Sustainability Roadmap	Water	Emissions	USP88	Medical Devices	Plastics
<ul style="list-style-type: none"><li>Environmental sustainability roadmap</li></ul>	<ul style="list-style-type: none"><li>A case for shifting to water stewardship in the BioPharma sector</li></ul>	<ul style="list-style-type: none"><li>Developing a harmonized approach to product carbon footprint for the biopharma industry (publication and webinar)</li></ul>	<ul style="list-style-type: none"><li>Bioreactivity testing in single use system biomanufacturing: Industry position paper</li></ul>	<ul style="list-style-type: none"><li>Sustainability for drug delivery devices. Recommendations for the industry across the value chain</li></ul>	<ul style="list-style-type: none"><li>Quantification of SUT waste for MAB's production</li></ul>
					



# Thank you

biophorum.com

hello@biophorum.com

**CONNECT  
COLLABORATE  
ACCELERATE™**